![Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators](/docs/US/2025-01-02/US20250002499A1/abs.jpg.600x600.jpg)
- Patent Title: Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators
-
Application No.: US18422517Application Date: 2024-01-25
-
Publication No.: US20250002499A1Publication Date: 2025-01-02
- Inventor: Sung David C. Kim , Zaixing Li , Chui Lu , Danuta Lubicka , James Neef , Hye-Yeon Park , Tejaskumar Pankajbhai Pathak , Amir Masoud Sadaghiani , Xilin Zhou
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Priority: WOPCT/CN2020/096177 20200615
- Main IPC: C07D491/048
- IPC: C07D491/048 ; C07D221/04
![Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators](/images/no_image.jpg)
Abstract:
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
Information query
